Stocks · News reference

Revelation Biosciences Q2 EPS $(0.87) Beats $(0.88) Estimate

Aug 6, 2026, 9:18 PMBenzinga Newsdesk

Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(0.87) per share which beat the analyst consensus estimate of $(0.88) by 1.14 percent. This is a 87.59 percent increase over losses of $(7.01) per share

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

REVB

Source: benzinga
Observed: Aug 6, 2026, 9:18 PM
Checked: Aug 6, 2026, 9:18 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 19, 2026, 1:05 PMBenzinga Newsdesk
Revelation Biosciences Selected Avance Clinical To Serve As CRO For Phase 2/3 Adaptive-Design TITAN Study For Evaluating Gemini In Patients With Acute Kidney Injury
– Study on track to begin later this year –Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat
Read original at benzinga
REVB
BenzingaAug 3, 2026, 1:03 PMBenzinga Newsdesk
Revelation Biosciences Cites Independent Market Assessment Indicating A $94B Total Addressable Market For Its Gemini Kidney Treatment
The independent market assessment evaluated Gemini for the treatment of Stage 2 and Stage 3 Acute Kidney Injury (AKI), a major cause of morbidity and mortality, which according to publicly available data affects more
Read original at benzinga
REVB
BenzingaJul 10, 2026, 8:07 PMBenzinga Newsdesk
Revelation Biosciences' Board Implements Shareholder Rights Plan, Declares Dividend Distribution Of One Right For Each Outstanding Common Stock
Read original at benzinga
REVB

Revelation Biosciences Q2 EPS $(0.87) Beats $(0.88) Estimate

Connected markets

Related headlines

Revelation Biosciences Selected Avance Clinical To Serve As CRO For Phase 2/3 Adaptive-Design TITAN Study For Evaluating Gemini In Patients With Acute Kidney Injury

Revelation Biosciences Cites Independent Market Assessment Indicating A $94B Total Addressable Market For Its Gemini Kidney Treatment

Revelation Biosciences' Board Implements Shareholder Rights Plan, Declares Dividend Distribution Of One Right For Each Outstanding Common Stock